GW&K Investment Management LLC raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 32.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,827,884 shares of the medical research company’s stock after purchasing an additional 698,463 shares during the quarter. GW&K Investment Management LLC owned 2.19% of NeoGenomics worth $51,920,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NEO. First Light Asset Management LLC grew its holdings in shares of NeoGenomics by 26.2% during the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock worth $179,158,000 after purchasing an additional 2,549,545 shares during the period. First Trust Advisors LP acquired a new stake in shares of NeoGenomics during the 1st quarter worth about $45,725,000. Dimensional Fund Advisors LP increased its position in shares of NeoGenomics by 9.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after purchasing an additional 225,588 shares during the last quarter. American Capital Management Inc. purchased a new stake in NeoGenomics in the 2nd quarter valued at about $32,648,000. Finally, Bank of New York Mellon Corp purchased a new stake in NeoGenomics in the 2nd quarter valued at about $10,744,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.
NeoGenomics Price Performance
Shares of NeoGenomics stock opened at $15.09 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.31 and a current ratio of 3.53. The business has a 50-day moving average of $17.37 and a 200 day moving average of $13.08. NeoGenomics, Inc. has a 12 month low of $7.07 and a 12 month high of $20.15.
NeoGenomics (NASDAQ:NEO – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $209.25 million for the quarter, compared to analyst estimates of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 earnings per share. Equities analysts anticipate that NeoGenomics, Inc. will post -0.06 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have weighed in on NEO. Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 target price on shares of NeoGenomics in a research note on Thursday, October 29th. Craig Hallum reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, July 29th. Piper Sandler reissued an “overweight” rating on shares of NeoGenomics in a research note on Wednesday, October 7th. Needham & Company LLC upped their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Finally, TD Cowen upped their price objective on shares of NeoGenomics from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.88.
Check Out Our Latest Research Report on NeoGenomics
About NeoGenomics
NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.
See Also
- Five stocks we like better than NeoGenomics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
